Laboratory aspects of haemophilia therapy

Haemophilia

Volumn 8, Issue 3, 2002, Pages 244-249

  Barrowcliffe, T W ^a   Mertens, K ^b   Preston, F E ^c   Ingerslev, J ^d  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b CENTRAL LABORATORY   (Netherlands)

^c UK NEQAS for Blood Coagulation   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING TEST; BLOOD COMPONENT THERAPY; COLORIMETRY; CONTROLLED STUDY; HEMOPHILIA; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL; PROTEIN PURIFICATION; THROMBOCYTE; VIRUS INACTIVATION; VIRUS INFECTION; CLINICAL CHEMISTRY; HEMOPHILIA A; IMMUNOLOGY; REVIEW; STANDARD;

CLINICAL CHEMISTRY TESTS; FACTOR VIII; HEMOPHILIA A; HUMANS; REFERENCE STANDARDS;

EID: 0036588693     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00602.x     Document Type: Article

References (23)

1. Over J. Methodology of the one-stage assay of Factor VIII (VIII. C). In: Nilsson I-M, Barrowcliffe TW, Schimpf K, eds. Factor VIII concentrates and their clotting activity. Scand J Haematol 1984; 33 (Suppl. 41): 13-24.
2. Barrowcliffe TW. Methodology of the two-stage assay of Factor VIII (VIII:C). In: Nilsson I-M, Barrowcliffe TW, Schimpf K, eds. Factor VIII concentrates and their clotting activity. Scand J Haematol 1984; 33 (Suppl. 41): 25-38.
3. Rosén S, Friberger P, Andersson M, Vinazzer H. A new chromogenic assay for determination of human Factor VIII:C Activity. In: Triplett DA, Skokie IL, eds. Advances in Coagulation Testing. College of American Pathologists, 1986: 255-60.
4. Barrowcliffe TW. Comparisons of 1-stage and 2-stage assays of factor VIII:C. In: Nilsson I-M, Barrowcliffe TW, Schimpf K, eds. Factor VIII concentrates and their clotting activity. Scand J Haematol 1984; 33 (Suppl. 41): 39-54.
5. Barrowcliffe TW. The one-stage versus the two-stage factor VIII assay. In: Triplett DA, Skokie, IL, eds. Advances in Coagulation. College of American Pathologists, 1986: 47-62.
6. Hubbard AR, Curtis AD, Barrowcliffe TW, Edwards SJ, Jennings CA, Kemball-Cook G. Assay of factor VIII concentrates: comparison of chromogenic and 2-stage clotting assays. Thrombosis Res 1986; 44: 887-91.
7. Barrowcliffe TW. Standardization and assay. Sem Thromb Haemost 1993; 19: 73-9.
8. Barrowcliffe TW, Factor VIII, Factor IX Subcommittee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70: 876-7.
9. Raut S, Heath A, Barrowcliffe TW. Establishment of the 6th International Standard for FVIII concentrate. Thromb Haemost 2001; 85: 1071-8.
10. Albertengo ME, Barrowcliffe TW, Oliva L, Bevan S, Raut S. New recombinant standard for FVIII concentrate gives same results as previous plasma derived standards on a range of FVIII products. Thromb Haemost 2000; 83: 789-90.
11. Hubbard AR, Rigsby P, Barrowcliffe TW. Standardisation of Factor VIII and von Willebrand Factor in plasma: calibration of the 4th International Standard (97/586). Thromb Haemost 2001; 85: 634-8.
12. Barrowcliffe TW, Watton J, Tubbs JE, Harman A, Kemball-Cook G. Potency of high purity factor VIII concentrates. Lancet 1990; 2: 124 (Letter).
13. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic FVIII concentrates. Br J Haematol 2002; in press.
14. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
15. Hubbard AR, Weller LJ, Bevan SA. Activation Profiles of FVIII in concentrates reflect one-stage/chromogenic potency discrepancies. Brit J Haematol 2002; in press.
16. Kirkwood TBL, Barrowcliffe TW. Discrepancy between 1-stage and 2-stage assay of factor VIII. C. Br J Haematol 1978; 40: 333-8.
17. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant factor VIII. Effect of assay method and standard. Br J Haematol 2001; 113: 533-6.
18. Lee CA, Owens D, Bray G et al. Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7.
19. Lee C, Barrowcliffe TW, Bray G et al. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996; 76: 950-6.
20. Kasper C, Aledort L, Counts R et al. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 1975; 34: 869-72.
21. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for Factor VIII. C inhibibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
22. Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001; 86: 1435-9.
23. Austen DEG, Lechner K, Rizza C, Rhymes IL. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost 1982; 47: 72-5.